
USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$83.09M
Market Cap
-
P/E Ratio
-0.2
EPS
$3.44
52 Week High
$0.98
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$285K |
| Total Revenue | $0 |
| Cost Of Revenue | $285K |
| Costof Goods And Services Sold | $285K |
| Operating Income | -$8.8M |
| Selling General And Administrative | $6.1M |
| Research And Development | $2.6M |
| Operating Expenses | $8.8M |
| Investment Income Net | - |
| Net Interest Income | $59K |
| Interest Income | $59K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $285K |
| Income Before Tax | -$8.8M |
| Income Tax Expense | $96K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$8.8M |
| Ebitda | -$8.5M |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Total Assets | $34M |
| Total Current Assets | $29M |
| Cash And Cash Equivalents At Carrying Value | $2.9M |
| Cash And Short Term Investments | $2.9M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $5.7M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $26M |
| Other Non Current Assets | - |
| Total Liabilities | $49M |
| Total Current Liabilities | $11M |
| Current Accounts Payable | $295K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $282K |
| Total Non Current Liabilities | $38M |
| Capital Lease Obligations | $589K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $589K |
| Other Current Liabilities | -$17M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$33M |
| Treasury Stock | - |
| Retained Earnings | -$407M |
| Common Stock | $4K |
| Common Stock Shares Outstanding | $40M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$16M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $285K |
| Capital Expenditures | $224K |
| Change In Receivables | - |
| Change In Inventory | -$19K |
| Profit Loss | - |
| Cashflow From Investment | -$12M |
| Cashflow From Financing | $27M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$285K |
| Total Revenue | $0 |
| Cost Of Revenue | $285K |
| Costof Goods And Services Sold | $285K |
| Operating Income | -$8.8M |
| Selling General And Administrative | $6.1M |
| Research And Development | $2.6M |
| Operating Expenses | $8.8M |
| Investment Income Net | - |
| Net Interest Income | $59K |
| Interest Income | $59K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $285K |
| Income Before Tax | -$8.8M |
| Income Tax Expense | $96K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$8.8M |
| Ebitda | -$8.5M |
| Net Income | -$11M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
BeyondSpring Inc. is a leading clinical-stage biopharmaceutical company based in New York, dedicated to advancing innovative immuno-oncology therapies to address unmet medical needs in cancer treatment. With a robust pipeline that includes its lead candidate, which has shown promising results in clinical trials, BeyondSpring aims to enhance the efficacy and safety of cancer care. By leveraging cutting-edge scientific research and strong partnerships, the company is positioned to make significant contributions to the field of oncology and deliver transformative therapies to patients worldwide.